Prot #G1T48-01: A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer